ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection
Department of Medicine, Division of Cardiovascular Medicine
Cardiology | Cardiovascular Diseases | Immunology and Infectious Disease | Infectious Disease | Virus Diseases
Cardiometabolic disease, especially hypertension, is a common risk factor for mortality among individuals with SARS-CoV-2 disease (COVID-19). The role of hypertension and vascular disease in COVID-19 has raised considerable debate around how to best manage anti-hypertensive therapy to alter disease trajectory. Given the role of the ACE2 receptor in SARS-CoV-2 viral entry6, angiotensin system modulation by ACE inhibitors (ACE-I) or angiotensin-II receptor blockers (ARBs) in clinical management have taken center stage in this controversy.
Infection, hypertension, COVID-19
DOI of Published Version
Shah R, Murthy VL, Koupenova M. ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection? Circ Res. 2020 Apr 17. doi: 10.1161/CIRCRESAHA.120.317174. Epub ahead of print. PMID: 32302248. Link to article on publisher's site
Shah R, Murthy VL, Koupenova-Zamor M. (2020). ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection. Coronavirus COVID-19 Publications by UMMS Authors. https://doi.org/10.1161/CIRCRESAHA.120.317174. Retrieved from https://escholarship.umassmed.edu/covid19/14